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Purpose: This paper aims to compare the clinical effectiveness of oral anti-osteoporosis drugs 
based on the observed risk of fracture while on treatment in primary care actual practice.
Materials and methods: We investigated two primary care records databases covering UK 
National Health Service (Clinical Practice Research Datalink, CPRD) and Catalan healthcare 
(Information System for Research in Primary Care, SIDIAP) patients during 1995–2014 and 
2006–2014, respectivey. Treatment-naive incident users of anti-osteoporosis drugs were included 
and followed until treatment cessation, switching, death, transfer out, or study completion. We 
considered hip fracture while on treatment as main outcome and major osteoporotic fractures (hip, 
clinical spine, wrist, and proximal humerus) as secondary outcome. Users of alendronate (reference 
group) were compared to those of (1) OBP, (2) strontium ranelate (SR), and (3) selective estrogen 
receptor modulators (SERMs), after matching on baseline characteristics using propensity scores. 
Multiple imputation was used to handle missing data on confounders and competing risk model-
ling for the calculation of relative risk according to therapy. Country-specific data were analyzed 
separately and meta-analyzed.
Results: A total of 163,950 UK and 145,236 Catalan patients were identified. Hip (sub-hazard ratio 
[SHR] [95% CI] 1.04 [0.77–1.40]) and major osteoporotic (SHR [95% CI] 1 [0.78–1.27]) fracture 
risks were similar among OBP compared to alendronate users. Both hip (SHR [95% CI] 1.26 
[1.14–1.39]) and major osteoporotic (SHR [95% CI] 1.06 [1.02–1.12]) fracture risk were higher in 
SR compared to alendronate users. SERM users had a reduced hip (SHR [95% CI] 0.75 [0.60–0.94]) 
and major osteoporotic (SHR [95% CI] 0.77 [0.72–0.83]) fracture risk compared to alendronate users.
Conclusion: We found a 26% excess hip fracture risk among SR compared to matched alendro-
nate users, in line with placebo-controlled RCT findings. Conversely, in a lower risk population, 
SERM users had a 25% reduced hip fracture risk compared to alendronate users. Head-to-head 
RCTs are needed to confirm these findings.
Keywords: pharmaco-epidemiology, anti-osteoporosis medication, osteoporosis, fracture risk, 
electronic health records
Introduction
Osteoporosis is characterized by progressive loss of bone mass and increased fracture 
risk.1 It is an age-related process, being more frequent among postmenopausal women 
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due to reduced estrogen levels during or after menopause.2,3 
The aim of anti-osteoporosis treatment is prevention of fragil-
ity fractures, which are associated with substantial disability, 
mortality, and considerable socioeconomic consequences.4,5 
Many randomized controlled trials (RCTs) have assessed 
the efficacy of different anti-osteoporosis drugs (AODs). 
However, the majority of studies used placebo or no treat-
ment as a control, with the resulting gap of knowledge on 
the comparative effectiveness of different alternatives.6 Few 
studies have directly compared AODs, having performed their 
primary analysis on a per-protocol rather than an intention-to-
treat set.7 Moreover, observational evidence comparing frac-
ture rates among different AOD users appears to be scarce.8,9 
The strict selection criteria used in most RCTs lead to 
significant differences between their participants and the users 
of drugs in the community.10,11 This is particularly relevant for 
certain subgroups of patients who, although at high fracture 
risk, are underrepresented or actively excluded in RCTs. In 
addition, several studies have reported suboptimal compliance 
and persistence with different anti-osteoporosis therapies in 
“real life” conditions,12–14 whereas some RCTs were designed 
to likely preselect high adherent patients.15 These distinctive 
conditions and characteristics might affect the external valid-
ity of the RCT findings, widening inconsistency between 
(RCT based) efficacy and “real-world” effectiveness.16
In this paper, we compare the anti-fracture effectiveness 
of available AODs based on the observed risk of fracture 
while on treatment using “real-world” data from the UK 
National Health Service (NHS) and Spanish healthcare 
records.
Materials and methods
study design 
A retrospective cohort study was conducted including all 
registered users of anti-osteoporosis medications. Data from 
two anonymized primary care outpatient records were used.
Data sources
Clinical Practice research Datalink (CPrD)
The CPRD database contains anonymized, computerized 
primary care outpatient records for a representative sample 
of the UK population.43 In addition to comprehensive demo-
graphic information, data include medication prescriptions 
by general practitioners (GPs), clinical events, referrals, and 
hospital admissions with their major outcomes in a sample 
of >7 million patients.17 The CPRD is administered by the 
Medicines and Healthcare Products Regulatory Agency and 
has broad National Research Ethics Service Committee ethics 
approval for purely observational research using the primary 
care data and established data linkages. For this study, an 
extract from 1994–2014 was used.
siDiaP
The Information System for Research in Primary Care 
(SIDIAP) database comprises primary care anonymized elec-
tronic medical records for >80% representative population of 
Catalonia.42 Similar to the UK NHS, the Catalan healthcare 
system is universal in coverage. Catalan GPs act as gatekeep-
ers to the system and are responsible for long-term prescrip-
tions. SIDIAP is linked to community pharmacy dispensations 
data and – for this specific study – hospital inpatient data as 
provided by the regional department of health. This study 
obtained approval from the SIDIAP Scientific Committee, 
responsible for reviewing protocols for scientific quality. We 
extracted data from SIDIAP participants from 2006 to 2014. 
Patient level data from both CPRD and SIDIAP used for 
the current study are only available for researchers mentioned 
in both data access applications.
Variables
Study exposure was defined as the use (as defined by GP pre-
scriptions in CPRD and dispensations in SIDIAP, considering 
that in both countries AODs are available only under prescrip-
tion) of alendronate (reference group) compared to (1) other 
oral bisphosphonates (OBP), (2) strontium ranelate (SR), 
and (3) selective estrogen receptor modulators (SERMs). 
Regarding the mechanism of action of the AODs included in 
the study, bisphosphonates inhibit osteoclastic bone resorp-
tion (specially on surfaces undergoing active resorption),18 
and appear to promote survival of osteocytes and osteoblasts 
as well.19 SR inhibits osteoclasts, which decreases bone 
resorption, while stimulating the formation of new bone 
tissue.20 SERMs, on the other hand, bind to estrogen recep-
tors and inhibit bone resorption, decreasing bone turnover 
as assessed by biochemical markers.21 The OBP included in 
this study were risedronate and ibandronate, as these are the 
most commonly prescribed OBP in both countries. Among 
SERMs, raloxifene was the most widely prescribed drug in 
both datasets, but bazedoxifene users were also identified 
and included in SIDIAP. Male selective estrogen receptor 
modulator (SERM) users were excluded from both datasets 
as SERMs are only licensed for use in women. Users of 
denosumab and teriparatide were also excluded due to low 
numbers (n = 29 and n = 7, respectively) in the CPRD dataset. 
Drug use was identified using previously validated lists of 
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British National Formulary codes for CPRD and  Anatomic 
Therapeutic Chemical classification codes, as created by the 
World Health Organization, for SIDIAP participants.
Outcomes studied were the first occurrence of either (1) 
hip fracture (primary), (2) major fracture (hip, spine, wrist, 
and proximal humerus), and (3) all (except digits and skull/
face) non-hip fractures (secondary outcomes) that were 
ascertained using READ/OXMIS (CPRD) and International 
Classification of Diseases (Hospital Episode Statistics and 
SIDIAP) codes.
Follow-up time was the duration between the start of treat-
ment (first AOD prescription) and end of treatment, defined 
as the first occurrence of the following events: (a) a gap in 
prescription/dispensation of 90 days or more, (b) switching 
to another AOD treatment, (c) transfer out of the study or 
loss to follow up, (d) end of study period (2014), (e) death, 
or (f) fracture. In cases (a) and (b), a washout period of 180 
days and an “on-prescription” period of 28 days was added 
to the last prescription date to account for carry over effect/s. 
Only naïve subjects to any available AOD/s were included 
and followed up during their first episode of treatment.
Confounders included in propensity score (PS) models 
were age, gender, body mass index (BMI), smoking, drink-
ing, fracture/s history, co-morbidities (Charlson index), and 
concomitant medications with an effect on bone health or 
fracture risk (oral glucocorticoids, anti-coagulants, hormone 
replacement therapy and contraceptives, aromatase inhibitors, 
calcium, corticosteroids, heparin, anxiolytics, and sedatives).
statistical methods
Multiple imputation22 was used to handle missing data within 
confounders, and PS matching22 was performed to minimize 
the effect of confounding. A Fine and Gray survival model23 
was used to estimate the risk of fracture while taking into 
account the competing risk of death.
Missing data
Assuming that data were missing at random, a series of 
multiple imputations were performed using multiple impu-
tation with chained equations methods. In brief, variables 
(confounders) associated with confounder/s (BMI, smoking, 
and drinking status) missingness and/or their values, as well 
as all variables in the PS/s, the study exposure, time to event, 
and outcome status were included in the multiple imputation 
models. Interactions as prespecified were included in the 
imputation equations. Multiple imputation by chained equa-
tions was performed using the Imputation by Chained Equa-
tions library implemented in the Stata software (version 13).
Ps matching
For an intervention with control and treatment arms, PS is 
defined as the probability of a subject j being in a given arm 
of the intervention C, conditional on a set of covariates X (i.e., 
prespecified confounders as described above). Patients who 
are similar with respect to the set of covariates are hypoth-
esized to have similar PS. PS are therefore commonly used 
to match “comparable” patients from control and treatment 
groups in a nonrandomized setting, thereby addressing the 
issue of confounding posed by the covariates. PS matching 
was performed for each drug comparison (i.e., alendronate vs 
OBP; alendronate vs SERMs; and alendronate vs SR users) 
to reduce the difference between the covariates/baseline 
characteristics of the control group (alendronate users) and 
each of the treatment groups.
First, logistic regression was performed to estimate the 
PS distributions for the control and treatment groups, by 
regressing treatment group assignment on baseline char-
acteristics. Next, subjects from the control and treatment 
groups were matched according to their respective PSs. 
The package MatchIt was implemented in software package 
R (version 3.3.2) to perform PS matching. The matching 
algorithm used was k-nearest neighbors (kNN), and a caliper 
width of 0.2 (a caliper width of 0.2 of the SD of the logit 
of the PS is expected to minimize the mean squared error 
in the treatment effect estimate) of the SD of the logit of 
the PS22 was used to restrict the kNN to search for matches 
within the caliper distance. A subject in the treatment group 
could be matched to up to four subjects in the control group, 
without replacement. 
Balance diagnostics
For a given variable, the standardized mean difference (SMD) 
in the distribution of the variable for the control and treatment 
groups was used to assess whether a good match had been 
obtained.22 Control and treatment groups were considered 
to be well-matched with respect to a variable if the absolute 
SMD was <0.1 after PS matching. Multivariable adjustment 
was performed for any confounders with a remaining SMD 
≥ 0.1 after PS matching.
survival analysis
Once a set of PS-matched subjects was obtained, the effect 
of treatment on the primary outcome (hip, major, or non-hip 
fracture) was estimated by directly comparing the outcomes 
and follow-up times in the treatment and control groups in the 
matched sample in a survival model. In order to estimate the 
relative risk (RR) of fracture in the presence of a  competing 
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risk of death, the proportional hazards regression model 
described by Fine and Gray23 was used (as implemented 
in the cpmrsk package in R) to calculate sub-hazard ratios 
(SHRs) for each of the outcomes accounting for a competing 
risk with death.24 Cumulative incidence fracture (CIF) curves 
stratified by drug use in the PS-matched sets were plotted to 
depict the observed differences in fracture risk in the different 
exposure groups over time.
number needed to treat (nnT)/number needed to 
harm calculation/s 
To determine the clinical effect size, we calculated the NNT 
to avoid one additional fracture at 3 and 5 years of follow-up 
(typical treatment duration), based on the registered fracture 
rates within each dataset. 
Meta-analysis
Meta-analyses were performed to compare and combine 
the results obtained for the CPRD and SIDIAP datasets. It 
was implemented in Review Manager (RevMan version 5.3; 
Cochrane, London, UK). Country-specific data (i.e., results 
for the CPRD and SIDIAP datasets) were analyzed separately 
and pooled using fixed effects model in case of homogene-
ity and random effects model if a significant between-study 
heterogeneity was found. Heterogeneity was assessed using 
the I2 test statistic and the c2 test (P < 0.01 indicated possible 
significance).
sub-group analyses
In addition to the primary analysis described above, a sec-
ondary analysis was performed in order to test for interac-
tion between the treatment and a given variable. To do so, 
an interaction term (treatment–variable) was included in 
the Fine and Gray model, in addition to the terms included 
above. Treatment–variable interaction was investigated for 
the following variables as prespecified per protocol: octoge-
narian (age 80 years), obesity (BMI > 30), gender, previous 
glucocorticoid use, and previous fracture history. Stratified 
analyses are reported in Table S1 and discussed where the p 
for interaction is borderline or significant (p < 0.1), consis-
tent in both CPRD and SIDIAP analyses, and considered of 
clinical relevance. 
sensitivity analyses
To assess if there was potential unresolved confounding due 
to any factors that were not accounted for in the PS match-
ing, a sensitivity analysis was performed using Rosenbaum’s 
boundaries testing.25 Rosenbaum’s “critical” γ inform on how 
imbalanced a strong unobserved confounder (with almost 
perfect prediction of the study outcome, i.e., fracture) needs 
to be between treatment/exposure groups in order to explain 
the observed association/s as reported after PS matching.25,26 
The “critical” γ of such imbalance that would make the 
observed association/s no longer significant (“critical” γ 
as denominated by Rosenbaum) is reported for each of the 
significant differences seen between PS-matched treatment 
group/s.
Results
study population
The cohort consisted of 163,950 and 145,236 patients 
included from the UK (CPRD) and Catalan (SIDIAP) popu-
lations, respectively, some of which were excluded when PS 
matching (Figure 1). Patients were followed-up for a median 
(interquartile range) of 1.45 (2.61) years and 5.34 (4.25) 
years in CPRD and SIDIAP, respectively. Baseline patient 
characteristics after matching are shown in Tables 1 and 2 
for CPRD and SIDIAP participants, respectively. Baseline 
characteristics of alendronate and users of other drugs were 
similar after propensity matching, with an absolute SMD 
below 10% for all baseline characteristics. When comparing 
each matched sample to one another, SERM users appeared to 
be younger than alendronate, OBP, and SR users within both 
datasets. We also found a higher prior hip fracture rate among 
SR compared to the remaining AOD users within the CPRD. 
Outcomes
alendronate versus other bisphosphonate users
When analyzing the difference in fracture rate among alen-
dronate and OBP users within the CPRD database, we identi-
fied 0.80 and 0.98 hip fractures per 100 person-years (PYs) at 
risk, 1.40 and 1.63 major osteoporotic fractures, and 1.19 and 
1.28 non-hip fractures, respectively. Hip, major osteoporotic, 
and non-hip fracture rates within the SIDIAP turned out to 
be 0.51 and 0.43, 3.01 and 2.51, and 2.55 and 2.14 among 
alendronate and OBP users, respectively (Table 3).
When fracture rates in alendronate and OBP users within 
the CPRD dataset where compared, the estimated RRs 
showed an increased hip (SHR [95% CI] 1.21 [1.11, 1.32]) 
and major osteoporotic (SHR [95% CI] 1.13 [1.05, 1.21]) 
fracture risk among users of OBP, while no significant differ-
ences were found for non-hip fractures (SHR [95% CI] 1.05 
[0.97, 1.13]). Among the patients in the SIDIAP identified 
as OBP users, there was an 11% decreased hip (SHR [95% 
CI] 0.89 [0.82, 0.97]), 12% lower major osteoporotic (SHR 
[95% CI] 0.88 [0.85, 0.91]), and 12 % reduced non-hip (SHR 
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[95% CI] 0.88 [0.84, 0.91]) fracture risk, when compared to 
the matched alendronate users. 
When findings from both cohorts were meta-analyzed, hip 
(SHR [95% CI] 1.04 [0.77, 1.40]), major osteoporotic (SHR 
[95% CI] 0.99 [0.76, 1.28]), and non-hip (SHR [95% CI] 0.96 
[0.81, 1.14]) fracture risk appeared to be similar among OBP 
compared to alendronate users (Figure S1).
alendronate versus sr users
The difference in fracture rate among alendronate and SR 
users within the CPRD was 1.44 and 1.92 hip fractures per 
100 PYs, 2.16 and 2.77 major osteoporotic fractures, and 
1.41 and 1.72 non-hip fractures, respectively. Hip, major 
osteoporotic, and non-hip fracture rates within the SIDIAP 
dataset turned out to be 0.49 and 0.59, 2.93 and 2.97, and 2.51 
Figure 1 recruitment of patients through the study within the CPrD and siDiaP datasets.
Abbreviations: aln, alendronate; CPrD, Clinical Practice research Datalink; OBP, other oral bisphosphonates; Ps, propensity score; sErM, selective estrogen-receptor 
modulator; siDiaP, information system for research in Primary Care; sr, strontium ranelate.
Total eligible
ALN users ALN usersALN users SR users SERM users
CPRD
CPRD
CPRD
CPRD
CPRD CPRD
CPRD
117,787
(90.6%)
(16.9%)
0 (0.0%)
0 (0.0%)
12,380
SIDIAP
SIDIAP
SIDIAP
SIDIAP SIDIAP
SIDIAP
15,675
114,288 (87.9%) 12,176 (9.4%) 3,046 (100%)
121,991
6,128
(39.77%)(49.27%)
36,066
(93.83%) 3 (0.15%)
7,960 (6.1%) 1,990 (99.9%)
9,282 (60.2%)37,128 (50.7%)15,410 (100%)60,814 (83,1%)
28,957 (99.9%)
45,112 (100%)73,193 (99.9%)
(12.1%) 1 (0.0%)
1 (0.0%) 0 (0.0%)
129,963 CPRD CPRD129,963 129,963 1,9933,046
45,112
28,948
73,194SIDIAP
PS matching
ALN excluded ALN excluded ALN excludedSR excluded SERM excluded
ALN included ALN included ALN included
OBP excluded
OBP included SR included SR included
PS matching PS matching
73,194 11,520SIDIAP
OBP users
CPRD 163,950
SIDIAP 145,236
SIDIAP 73,194 15,410
Table 1 Baseline patient characteristics for CPrD after propensity score matching
Patient characteristics ALN OBP SMD ALN SR SMD ALN SERM SMD
no. of patients after matching 114,288 28,948 12,176 3,046 7,960 1,990
aged ≤63: n (%) 23,514 (20.6) 5,884 (20.3) <0.01 1,062 (8.7) 288 (9.5) <0.01 4,275 (53.6) 1,032 (51.7) 0.01
aged 64 ≤ 71: n (%) 23,670 (20.7) 6,076 (21.0) <0.01 1,460 (12.0) 363 (11.9) <0.01 1,919 (24.1) 524 (26.3) <0.01
aged 72 ≤ 77: n (%) 22,928 (20.1) 5,875 (20.3) <0.01 2,028 (16.7) 464 (15.2) <0.01 938 (11.8) 215 (10.8) 0.02
aged 78 ≤ 83: n (%) 23,053 (20.2) 5,918 (20.4) <0.01 3045 (25.0) 721 (23.7) <0.01 517 (6.5) 143 (7.2) <0.01
aged ≥84: n (%) 21,123 (18.5) 5,195 (17.9) <0.01 4,581 (37.6) 1210 (39.7) 0.01 323 (4.1) 79 (1.0) 0.01
gender female: n (%) 93,259 (81.6) 23,713 (81.9) <0.01 10,260 (84.3) 2,576 (84.6) <0.01 7,960 (100) 1,990 (100) na
BMi*: mean (sD) 25.2 (6.7) 25.7 (6.7) <0.01 24.1 (6.7) 23.83 (7.1) <0.01 25.30 (7.0) 25.5 (6.8) 0.02
Current smoker**: n (%) 37,266 (32.6) 9,192 (31.8) <0.01 3,755 (30.8) 921 (30.3) 0.01 2,268 (28.4) 524 (26.3) <0.01
heavy alcohol drinker***: n (%) 5,102 (4.5) 1,192 (4.45) <0.01 596 (4.9) 165 (5.4) <0.01 274 (3.4) 55 (3.4) <0.01
Charlson index: mean (sD) 0 (2) 0 (2) <0.01 0 (2) 1 (2) <0.01 0 (0) 0 (0) 0.03
Calcium use: n (%) 24,631 (21.6) 6,633 (22.9) 0.02 3,531 (29.3) 896 (29.4) <0.01 1,657 (20.8) 411 (20.6) <0.01
Corticosteroids use: n (%) 36,158 (31.6) 9,294 (32.1) <0.01 1,820 (14.9) 467 (15.3) <0.01 907 (11.4) 219 (11.0) 0.03
Prior hip fracture: n (%) 10,164 (8.9) 2,610 (9.0) <0.01 3,008 (24.7) 772 (25.3) 0.02 218 (2.7) 45 (2.3) <0.01
Prior non-hip fracture: n (%) 19,010 (83.6) 4,732 (16.3) <0.01 2,369 (19.5) 598 (19.6) 946 (11.9) 242 (12.1) 0
Notes: *Percentage of BMi missing before imputation and Ps matching: 45.3% among aln users, 48.0% among OBP users, 44.4% among sr users, 57.8% among sErM 
users. **Percentage of smoking missing before Mi and Ps matching: 21.6% among aln users, 23.7% among OBP users, 14.2% among sr users, 37.2% among sErM users. 
***Percentage of drinking missing before Mi and Ps matching: 54.5% among aln users, 55.4% among OBP users, 55.3% among sr users, 60.6% among sErM users. 
Abbreviations: aln, alendronate; BMi, body mass index; CPrD, Clinical Practice research Datalink; Mi, multiple imputation; na, not applicable; OBP, other oral 
bisphosphonates; Ps, propensity score; sD, standard deviation; sErM, selective estrogen-receptor modulator; sMD, standardized mean difference; sr, strontium ranelate.
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and 2.44 among alendronate and SR users, respectively. The 
probability of not having a fracture was compared between 
alendronate users and matched SR users as shown using a 
CIF (Figure 2).
There were no statistically significant differences in 
fracture risk in CPRD (SHR [95% CI] 1.18 [0.94, 1.48] 
for hip fracture, SHR [95% CI] 1.14 [0.94, 1.39] for major 
osteoporotic fracture, and SHR [95% CI] 1.13 [0.89, 1.43] 
for non-hip fracture). However, within the SIDIAP dataset, 
hip and major osteoporotic fracture risk appeared to be 28% 
(SHR [95% CI] 1.28 [1.15, 1.42]) and 6% (SHR [95% CI] 
1.06 [1.01, 1.11]) higher, respectively, among SR compared 
to alendronate users. Non-hip fracture risk did not show any 
difference between both AODs (SHR [95% CI] 1.01 [0.97, 
1.07]). When findings from both cohorts were meta-analyzed, 
we identified a 26% (pooled SHR [95% CI] 1.26 [1.14–1.39]) 
Table 2 Baseline patient characteristics for siDiaP after propensity score matching
Patient characteristics ALN OBP SMD ALN SR SMD ALN SERM SMD
no. of patients after matching 73,193 45,112 60,814 15,410 37,128 9,282
age
aged ≤63: n (%) 14,654 (20.0) 9,653 (21.0) 0.02 12,257 (20.2) 3,221 (20.9) <0.01 13,453 (34.0) 4,839 (42.0) 0.03
aged 64 ≤ 71: n (%) 13,473 (18.4) 8,684 (19.3) 0.01 11,556 (19.0) 2,902 (18.8) <0.01 10,899 (27.5) 2,876 (25.0) 0.02
aged 72 ≤ 77: n (%) 14,588 (19.9) 9,132 (20.3) 0 12,423 (20.4) 3,054 (19.8) <0.01 7,830 (20.1) 1,986 (17.2) <0.01
aged 78 ≤ 83: n (%) 15,622 (21.3) 9,512 (21.1) <0.01 13,004 (21.4) 3,262 (21.2) <0.01 4,745 (10.7) 1,078 (9.4) <0.01
aged ≥84: n (%) 14,856 (20.3) 8,131 (18.0) 0.03 1,157 (19.0) 2,971 (19.3) <0.01 2,693 (7.7) 741 (6.4) <0.01
Female: n (%) 58,751 (80.3) 34,923 (77.4) 0.07 49,766 (81.8) 12,671 (82.2) <0.01 37,128 (100) 9,282 (100) na
BMi*: mean (sD) 27.68 (6.3) 27.94 (6.3) 0.03 28.05 (6.2) 28.30 (6.4) 0.03 27.41 (6.3) 27.39 (6.1) <0.01
Current smoker**: n (%) 9,146 (12.5) 5,246 (11.6) 0.01 6,922 (11.4) 1,517 (9.8) <0.01 5,546 (14.0) 1,551 (13.5) <0.01
heavy alcohol drinker***: n (%) 928 (1.3) 606 (1.3) <0.01 753 (1.2) 175 (1.1) <0.01 643 (1.6) 190 (1.6) <0.01
Charlson index: mean (sD) 0 (1) 0 (1) 0.03 0 (1) 0 (1) <0.01 0 (1) 0 (1) 0.03
Prior hip fracture: n (%) 2,536 (3.5) 1,035 (2.3) 0.02 2,106 (3.4) 528 (3.4) <0.01 335 (0.8) 72 (0.6) 0.02
Prior non-hip fracture: n (%) 10,929 (14.9) 4,995 (11.1) 0.03 8,368 (13.8) 2,048 (13.3) <0.01 3,087 (7.5) 745 (6.5) <0.01
Notes: *Percentage of BMi missing before Mi and Ps matching: 24.1% among aln users, 27.1% among OBP users, 25.6% among sr users, 31.6% among sErM users. 
**Percentage of smoking missing before Mi and Ps matching: 14.7% among aln users, 17.3% among OBP users, 16.2% among sr users, 19.5% among sErM users. 
***Percentage of drinking missing before Mi and Ps matching: 63.9% among aln users, 74.6% among OBP users, 69.0% among sr users, 74.6% among sErM users.
Abbreviations: aln, alendronate; BMi, body mass index; Mi, multiple imputation; na, not applicable; OBP, other oral bisphosphonates; Ps, propensity score; sD, standard 
deviation; sErM, selective estrogen-receptor modulator; siDiaP, information system for research in Primary Care; sMD, standardized mean difference; sr, strontium 
ranelate.
Table 3 results of the association between drug use (compared to “comparable” alendronate users) and fracture risk in the propensity-
matched populations
Fracture Drug CPRD SIDIAP
IR (100 PYs) SHR [95% CI] IR (100 PYs) SHR [95% CI]
hip aln 0.80 ref 0.51 ref
OBP 0.98 1.21 (1.11–1.32) 0.43 0.89 (0.82–0.97)
aln 1.44 ref 0.49 ref
sr 1.92 1.18 (0.94–1.48) 0.59 1.28 (1.15–1.42)
aln 0.31 ref 0.23 ref
sErMs 0.26 0.86 (0.51–1.45) 0.16 0.73 (0.57–0.93)
Major  
osteoporotic
aln 1.40 ref 3.01 ref
OBP 1.63 1.13 (1.05–1.21) 2.52 0.88 (0.85–0.91)
aln 2.16 ref 2.93 ref
sr 2.77 1.14 (0.94–1.39) 2.97 1.06 (1.01–1.11)
aln 0.84 ref 2.32 ref
sErMs 0.67 0.81 (0.57–1.15) 1.74 0.77 (0.72–0.80)
non-hip aln 1.19 ref 2.55 ref
OBP 1.28 1.05 (0.97–1.13) 2.14 0.88 (0.84–0.91)
aln 1.41 ref 2.51 ref
sr 1.72 1.13 (0.89–1.43) 2.44 1.01 (0.97–1.07)
aln 0.98 ref 2.11 ref
sErMs 0.74 0.76 (0.55–1.03) 1.59 0.774 (0.72–0.84)
Abbreviations: aln, alendronate; CPrD, Clinical Practice research Datalink; ir, incidence rate; OBP, other oral bisphosphonates; ref, reference; sErM, selective 
estrogen-receptor modulator; shr, sub-hazard ratio; siDiaP, information system for research in Primary Care; sr, strontium ranelate.
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and 6% (pooled SHR [95% CI] 1.06 [1.02–1.12]) higher hip 
and major osteoporotic fracture risk, respectively, among SR 
compared to alendronate users (Figure S2). We did not find 
any non-hip fracture risk difference between alendronate and 
SR users (SHR [95% CI] 1.01 [0.97, 1.05]).
alendronate versus sErM users
All observed fracture rates turned out to be lower among 
SERM compared to alendronate users, within both the CPRD 
and SIDIAP datasets. We identified 0.31 and 0.26 hip frac-
tures per 100 PYs at risk, 0.84 and 0.67 major osteoporotic 
fractures, and 0.98 and 0.74 non-hip fractures among alen-
dronate and SERMs users registered in CPRD, respectively. 
In the same way, hip, major osteoporotic, and non-hip fracture 
rates proved to be 0.23 and 0.16, 2.32 and 1.74, and 2.11 
and 1.59 within the SIDIAP database. As shown in the CIF 
plot in Figure 3, we compared the probability of not having 
a fracture between alendronate and SERM users. 
Statistically nonsignificant fracture risk differences were 
seen in CPRD among SERM users (SHR [95% CI] 0.86 
[0.51, 1.45] for hip fracture, SHR [95% CI] 0.81 [0.57, 1.15] 
for major osteoporotic fracture, and SHR [95% CI] 0.76 
[0.56, 1.03] for non-hip fracture). However, when assessing 
the fracture risk difference within the SIDIAP, we identified 
a 27% lower hip (SHR [95% CI] 0.73 [0.57, 0.93]), a 23% 
reduced major osteoporotic (SHR [95% CI] 0.77 [0.72, 
Figure 2 CiF plot, representing the probability of having a fracture among alendronate and sr users within the CPrD dataset (top), and siDiaP dataset (bottom).
Abbreviations: CiF, cumulative incidence fracture; CPrD, Clinical Practice research Datalink; siDiaP, information system for research in Primary Care; sr, strontium 
ranelate.
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0.80]), and a 23% reduction in non-hip fracture risk (SHR 
[95% CI] 0.77 [0.72, 0.84]) was observed among SERM 
compared to alendronate users.
Lastly, as shown in Figure S3, all observed fracture risks 
appeared to be lower among SERM compared to alendronate 
users after meta-analyzing data from both UK and Catalan 
populations. We found a 25% hip (SHR [95% CI] 0.75 
[0.60, 0.94]), 23% major osteoporotic (SHR [95% CI] 0.77 
[0.72, 0.83]), and 23% non-hip (SHR [95% CI] 0.77 [0.72, 
0.83]) fracture risk reduction among SERM compared to 
alendronate users. 
Although the observed ranges of RRs for SR were not 
significant in the UK population, the NNT to avoid an 
additional hip fracture over 3 to 5 years of treatment with 
alendronate compared to SR was calculated to be 69 to 42, 
respectively. For those patients included in the SIDIAP, the 
estimated NNT would be 333 and 200. Moreover, the NNT 
to avoid an additional major osteoporotic fracture at 5 years 
of treatment with alendronate when compared to SR within 
the CPRD and SIDIAP datasets was calculated to be 33 and 
500, respectively.
On the other hand, the NNTs to avoid one hip, major 
osteoporotic, and non-hip fracture at 5 years of follow-up 
associated with SERM use within the CPRD were calcu-
lated to be 400, 117, and 83, respectively. For those patients 
included in the SIDIAP, the corresponding NNTs would be 
286, 34, and 38. 
analysis of interactions
We performed tests for interaction in order to assess the 
association between different anti-osteoporosis medications 
and fracture risk in relation to patients’ age, BMI, gender, 
Figure 3 CiF plot representing the probability of having a fracture among alendronate and sErM users within the CPrD dataset (top) and siDiaP dataset (bottom).
Abbreviations: CiF, cumulative incidence fracture; CPrD, Clinical Practice research Datalink; sErM, selective estrogen-receptor modulator; siDiaP, information system 
for research in Primary Care.
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oral steroid use, and previous fracture history. Detailed find-
ings are reported in Table S1, and most clinically relevant 
and consistent (in both CPRD and SIDIAP) results are sum-
marized here.
SERMs appeared to have a significantly different anti-
fracture effectiveness depending on whether a previous 
fracture had been reported or not. Within CPRD, we demon-
strated a 37% (SHR 0.63 [95% CI 0.40–0.99]) lower major 
osteoporotic fracture risk among SERM users in primary 
prevention, that was not replicated in secondary prevention 
(SHR 1.33 [95% CI 0.74–2.40]). Within SIDIAP, hip and 
major osteoporotic fracture risk turned out to be 39% (SHR 
0.61 [95% CI 0.48–0.78]) and 31% (SHR 0.69 [95% CI 
0.64–0.74]) lower, respectively, among users of SERMs in 
primary prevention, which was again not replicated among 
patients in secondary fracture prevention (SHR 0.94 [95% CI 
0.54–1.63] and SHR 0.85[95% CI 0.70–1.03], respectively).
sensitivity analysis
Within the CPRD, Rosenbaum bounds analyses found a “crit-
ical” γ of 1.1 for hip and 1.0 for major osteoporotic fractures 
among SR versus alendronate users and 1.1 for both types of 
fracture among SERM versus alendronate users. Within the 
SIDIAP, the sensitivity analysis found a “critical” γ of 1.1 
for hip and 1.2 for major osteoporotic fractures among SR 
versus alendronate users and 1.2 for both type of fractures 
among users of SERMs versus alendronate. 
Discussion
We report on the anti-fracture effectiveness of different AODs 
while used in “real life” conditions in the UK and Catalan 
primary care settings. First, risk of fracture (of any location 
studied) while on treatment with alendronate was similar 
to that while on treatment with OBP. Second, anti-fracture 
effectiveness was better for alendronate compared to SR, with 
a 26% hip and 6% major fracture risk increase among users 
of the latter. Finally, SERMs appeared to be more effective 
at reducing fractures among lower risk patients, with an 25% 
hip and 23% major osteoporotic fracture risk reduction com-
pared to matched alendronate users of similar characteristics.
According to most of the literature reviewed, no signifi-
cant anti-fracture effectiveness difference has been reported 
between alendronate and OBP users, which is consistent 
with our results. Two meta-analysis assessing the efficacy 
of alendronate and risedronate (most commonly used “other 
bisphosphonate”) relative to placebo, resulted in an RR of 
vertebral fracture of 0.55 (95% CI 0.45–0.67) and 0.61 
(95% CI 0.50–0.76), an RR of hip fracture of 0.60 (95% 
CI 0.40–0.92) and 0.74 (95% CI 0.59–0.94), and an RR for 
other non-vertebral fractures of 0.84 (95% CI 0.74–0.94) 
and 0.80 (95% CI 0.72–0.90), respectively.27,28 However, the 
meta-analysis carried out by Freemantle et al, comparing the 
anti-fracture efficacy of osteoporosis therapies, demonstrated 
a significant hip fracture reduction with risedronate compared 
to placebo (RR 0.74 [95% CI 0.59–0.94]) that was not repli-
cated with alendronate (RR 0.65 [95% CI 0.41–1.03]).29 Our 
findings provide further evidence regarding the comparative 
anti-fracture effectiveness of OBP and demonstrate that 
risedronate can remain as an effective alternative when alen-
dronate is not tolerated, as recommended in current National 
Institute for Health and Care Excellence guidelines.2,3
Regarding SR, hip and major osteoporotic fracture risk 
appeared to be increased (by 26% and 6%, respectively) 
among its users compared to matched participants who 
received alendronate. These findings are supported by the 
results from previous RCTs: while placebo-controlled trials 
failed to demonstrate hip fracture risk reduction efficacy with 
SR (with the exception of a post hoc subgroup analysis in 
high risk groups),30,31 data from the Fracture Intervention Trial 
(FIT) RCT found that alendronate was efficacious at reducing 
hip fracture risk by 53%.32 According to our data on “real 
life” users of these drugs in the UK NHS, one hip fracture 
would occur for each 42 subjects treated with SR instead of 
alendronate for 5 years (typical treatment duration). However, 
it should also be noted that, since August 2017, SR has been 
discontinued worldwide by manufacturers alluding to com-
mercial reasons and it is no longer available for patients.33
On the other hand, we demonstrate that – in a lower risk 
population, with annual fracture rates of approximately 
3/1,000 PYs at the hip and 8/1,000 PYs at “major osteopo-
rotic” sites – a 25% RR reduction in hip and an almost 23% 
reduction in major osteoporotic fracture risk is seen among 
SERMS compared to alendronate users. Such improved 
anti-fracture effectiveness was only seen in primary preven-
tion, with no significant differences in secondary prevention 
settings. According to some clinical specialists, the SERM 
raloxifene might be a beneficial option particularly for 
younger postmenopausal woman, due to its potential and 
simultaneous benefit on vertebral fracture and breast cancer 
prevention.2,34 Our findings suggest that in younger patients 
(see baseline characteristics of SERM users compared to, 
for example, users of other bisphosphonates) and when a 
previous fracture has been ruled out (primary prevention), 
SERMs might be preferable to alendronic acid. However, the 
largest trial (the “Multiple Outcomes of Raloxifene Evalu-
ation” [MORE] study) comparing raloxifene to placebo did 
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not demonstrate any significant hip fracture risk reduction, 
being just effective in vertebral fracture prevention (30% RR 
reduction for the 60 mg/day and 50% for the 120 mg/day 
group).34 This might be explained by the different risk profile 
(hip fracture cumulative incidence of 1.5% after 36 months in 
the RCT compared to 1.1% and 3.5% hip fractures in 3 years 
within the CPRD and SIDIAP SERM users, respectively), 
differences in compliance resulting in lack of anti-fracture 
effectiveness among bisphosphonate users, and/or limited 
power of the MORE trial compared to our study participants.
strengths and limitations
Our study has some limitations. First, the observational 
nature of our data can be a source of potential confound-
ing, due to the lack of randomization. Despite our attempt 
to minimize such confounding by indication using PS 
matching methods, unobserved confounders might be 
present, including (but not only) differences in baseline 
bone mineral density. To assess the potential impact of 
such confounding, a sensitivity analysis (Rosenbaum 
boundaries) was conducted, which suggested that both our 
findings of differential anti-fracture effectiveness of SERM 
and SR (compared to alendronate) were sensitive to the 
presence of imbalanced unobserved confounders, with an 
estimated γ of 1.20: this means that for any unmeasured 
confounder with a strong association with fracture risk 
(i.e., that almost perfectly predicted fracture/s), that con-
founder would need to be associated with a 20% increase 
in the probability of receiving SERM/SR (rather than 
alendronate) to explain the study findings. Such imbalances 
in the prevalence of, for instance, severe osteoporosis in 
users of SR or SERMs compared to alendronate are not 
unlikely, and thus our findings must be interpreted with 
caution and confirmed by further head-to-head RCTs. On 
the other hand, information on secondary care outpatient 
therapies was available in SIDIAP, but not in CPRD. This 
could partially explain some of the observed discrepancies 
in the results obtained from both databases. Differences in 
prescribing patterns between both countries might also be 
a potential source of unobserved confounding and should, 
accordingly, be considered. Although routinely collected 
data enable better knowledge of adherence and persistence 
to therapies, drug use within registry may not equate drug 
compliance. In addition, registration errors by GPs could 
underestimate the real fracture incidence, although large 
samples of data from CPRD have previously been suc-
cessfully used to assess fracture risk,35,36 the diagnoses of 
fracture (and specially hip fracture) have been validated 
previously in both CPRD37 and SIDIAP,38 and the rates of 
fractures seen are similar to those expected from the known 
epidemiology.39 Finally, a proportion of the fractures seen 
in this study might be trauma rather than fragility related. 
A recent study performed in a sample of such fractures in 
SIDIAP has demonstrated that a high proportion (92% of 
hip, 88% of vertebral, and 81% of all major fractures) of 
fractures recorded in this database are indeed of osteopo-
rotic nature.40
In terms of strengths, the large and representative 
population included in the SIDIAP and CPRD datasets are 
the backbone of this binational cohort and meta-analysis, 
which allowed us to assess the anti-fracture effectiveness of 
the AODs as used by potentially all NHS patients in actual 
practice conditions. The breadth of data available allowed 
us to study various potential interactions with baseline 
characteristics in an attempt to identify the best therapy for 
each patient subgroup. Moreover, we used PS adjustment to 
accurately estimate RRs, which is currently recognized as the 
best analytical approach to reduce the effects of confounding 
by indication.41 
Conclusion
In this multi-database study, we found a 26% increased hip 
fracture risk among users of SR compared to matched users 
of alendronate, which is consistent with previous placebo-
controlled RCT findings. Conversely, in a lower risk popu-
lation without any previously registered fragility fracture, 
SERM users had a 25% reduced hip fracture risk compared to 
alendronate users. Head-to-head RCTs are needed to confirm 
these novel findings.
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Supplementary materials
Figure S1 hip, major osteoporotic, and non-hip fracture hr among other 
bisphosphonate users compared to alendronate users, after meta-analyzing data 
from CPrD and siDiaP datasets.
Abbreviations: CPrD, Clinical Practice research Datalink; hr, hazard ratio; 
siDiaP, information system for research in Primary Care.
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Figure S2 hip, major osteoporotic, and non-hip fracture hr among strontium 
ranelate users compared to alendronate users, after meta-analyzing data from 
CPrD and siDiaP datasets.
Abbreviations: CPrD, Clinical Practice research Datalink; hr, hazard ratio; 
siDiaP, information system for research in Primary Care.
Hip fracture risk
HR
CPRD
SIDIAP
CPRD
SIDIAP
CPRD
SIDIAP
IV, random, 95% CI
0.01
Favors (strontium ranelate) Favors (alendronate)
0.1 1 10 100
0.01
Favors (strontium ranelate) Favors (alendronate)
0.1 1 10 100
0.01
Favors (strontium ranelate) Favors (alendronate)
0.1 1 10 100
Major osteoporotic fracture risk
Non-hip fracture risk
HR
HR
IV, random, 95% CI
IV, random, 95% CI
Figure S3 hip, major osteoporotic, and non-hip fracture hr among sErM 
compared to alendronate users, after meta-analyzing data from CPrD and siDiaP 
datasets.
Abbreviations: CPrD, Clinical Practice research Datalink; hr, hazard ratio; 
sErM, selective estrogen receptor modulator; siDiaP, information system for 
research in Primary Care.
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